The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Insurance coverage for obesity treatment varies widely across insurance plans and health systems.
“Annual out-of-pocket costs for GLP-1 RAs can exceed several thousand dollars and insurance coverage for obesity treatment varies widely across insurance plans and health systems.4,103”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [4]
Annual out-of-pocket costs for GLP-1 RAs can exceed several thousand dollars.
“Annual out-of-pocket costs for GLP-1 RAs can exceed several thousand dollars and insurance coverage for obesity treatment varies widely across insurance plans and health systems.4,103”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Years of Life Lost Due to Obesity
Fontaine, K. R., Redden, D. T., Wang, C., Westfall, A. O., & Allison, D. B. (2003) · JAMA · doi:10.1001/jama.289.2.187 · Cited by 2,498
Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.23332 · Cited by 172
Global cost of overweight and obesity will hit $4.32tn a year by 2035, report warns
Mahase, E. (2023) · BMJ · doi:10.1136/bmj.p523 · Cited by 75
Adding Cost-effectiveness to Define Low-Value Care
Pandya, A. (2018) · JAMA · doi:10.1001/jama.2018.2856 · Cited by 73
GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
Monti, G., Moreira, D. G., Richner, M., Mutsaers, H. A. M., Ferreira, N., & Jan, A. (2022) · Cells · doi:10.3390/cells11132023 · Cited by 72
Life Years Lost Associated with Obesity-Related Diseases for U.S. Non-Smoking Adults
Chang, S., Pollack, L. M., & Colditz, G. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066550 · Cited by 72
FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade
Idrees, Z., Cancarevic, I., & Huang, L. (2022) · Cureus · doi:10.7759/cureus.29262 · Cited by 64
Estimated Sustainable Cost-Based Prices for Diabetes Medicines
Barber, M., Gotham, D., Bygrave, H., & Cepuch, C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.3474 · Cited by 62
State coverage and reimbursement of antiobesity medications in Medicaid.
Liu, B. Y., & Rome, B. N. (2024) · JAMA · doi:10.1001/jama.2024.3073 · Cited by 46
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
Giugliano, D., Scappaticcio, L., Longo, M., Bellastella, G., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01400-9 · Cited by 44
Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists
Emanuel, E. J., Dellgren, J. L., McCoy, M. S., & Persad, G. (2024) · New England Journal of Medicine · doi:10.1056/nejmp2400978 · Cited by 44
Self-citationConfronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies
Horrow, C., & Kesselheim, A. S. (2023) · Health Affairs · doi:10.1377/hlthaff.2023.00527 · Cited by 32
Cherla, A., Howard, N., & Mossialos, E. A. (2020) · Health Economics Policy and Law · doi:10.1017/s1744133120000031 · Cited by 16
Auty, S. G., Griffith, K. N., Shafer, P. R., Gee, R. E., & Conti, R. M. (2022) · Journal of Health Politics Policy and Law · doi:10.1215/03616878-10041121 · Cited by 13
Jahromi, A. S., & Rahmanian, K. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_667_20 · Cited by 10
Krychtiuk, K. A., Andersson, T. L., Bodesheim, U., Butler, J., Curtis, L. H., Elkind, M. S. V., Hernandez, A. F., Hornik, C. P. V., Lyman, G. H., Khatri, P., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.01.004 · Cited by 8
Life Years Lost Associated with Obesity-Related Diseases for U.S. Non-Smoking Adults.Preprint
Chang, S., Pollack, L. M., & Colditz, G. A. (2013) · SSRN Electronic Journal · doi:10.2139/ssrn.2371624 · Cited by 3
Flagged first, then by citations
1 of the 19 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Pearson, S. D., Whaley, C. M., & Emond, S. K. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0083 · Cited by 55
“Those critical of current pricing have raised multiple considerations that they feel trump a pure cost–effectiveness paradigm [22] .”
Jackson, S. E., Brown, J., Llewellyn, C. H., Mytton, O. T., & Shahab, L. (2026) · BMC Medicine · doi:10.1186/s12916-025-04528-7 · Cited by 33
Rehm, J. T., Assanangkornchai, S., Hendershot, C. S., Franklin, A., Neufeld, M., Hassan, A. S., & Shield, K. D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01496-5 · Cited by 25
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 17
GLP-1 receptor agonists for obesity: eligibility across 99 countries
Yoo, S. G. K., Teufel, F., Theilmann, M., Si, Y., Touré, E. A., Aryal, K. K., Bärnighausen, T., Bait, A., Barreto, M., Bovet, P., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00356-0 · Cited by 17
Yammine, L., Grigson, P. S., Schmitz, J. M., Evans, B., & Hendershot, C. S. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00657-4 · Cited by 14
Alsuhibani, A. A., Alrasheed, M. A., Alhomoud, I. S., Alsahali, S. M., Almalki, Z. S., & Guo, J. J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1537181 · Cited by 10
Jackson, S. E., Brown, J., Llewellyn, C. H., Mytton, O. T., & Shahab, L. (2025) · medRxiv · doi:10.1101/2025.06.06.25329114 · Cited by 5
Weight maintenance after discontinuation of GLP-1 therapies
Moiz, A., Filion, K. B., Knäuper, B., Tsoukas, M. A., Brazeau, A.-S., Zolotarova, T., Lelièvre, A., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103992 · Cited by 7
“4,103 Many plans deny coverage for individuals without diabetes or impose duration limits, while intermittent supply shortages have further disrupted continuity of care.”
Liraglutide for adults living with obesity
Meza, N., Bracchiglione, J., Liquitay, C. M. E., Eva Madrid, A., Varela, L. B., Guo, Y., Urrútia, G., er, S. F. S., Tiller, S., Shokraee, K., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016017 · Cited by 5
Dellgren, J. L., Emanuel, E., & Persad, G. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01317 · Cited by 4
Self-citationThe GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025Preprint
Falster, M. O., Costa, J. D. O., Milder, T. Y., Carson, J. M., Shadbolt, C., Neuen, B. L., Arnott, C. G., Wilson, A. J., Jun, M., Pratt, N. L., et al. (2025) · medRxiv · doi:10.1101/2025.10.30.25339120 · Cited by 2
Barrett, R., Smith, A., Gorry, C., Doran, S., Barry, M., & McCullagh, L. (2025) · Value in Health · doi:10.1016/j.jval.2025.03.017 · Cited by 1
Glucagon-Like Peptide-1-Receptor Agonist Treatment of Obesity: Is It Cost-Effective and Equitable?
Hertzer, L., & Siegel, R. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114779 · Cited by 1
Duits, A. J., Samson, M. J., Gans, R. O. B., Gerstenbluth, I. I., Busari, J. O., & Schnog, J. B. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1582732 · Cited by 1
Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?
Kumar, S., Olson, O., & Kellogg, T. A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01347-2 · Cited by 1
What role will physiological resilience play in brown-white fat dynamic in obesity management?
Zayachkivska, O., Kovalchuk, I., Muzyka, I., & Savytska, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1691149 · Cited by 2
Antiobesity Interventions in Living Organ Donor Candidates: Ethical and Policy Considerations
Abbasi, A. B., Zambeli-Ljepović, A., Stock, P. G., Kimberly, L., & Orandi, B. J. (2026) · Transplantation · doi:10.1097/tp.0000000000005719 · Cited by 1
TIRZEPATIDA E ESTÉTICA CORPORAL: POTENCIAL TERAPEUTICO NO EMAGRECIMENTO E SEUS EFEITOS ADVERSOS
de Gois, N. P., Mora, R., de Mendonça, G. J. G., Clavijo, B., do Nascimento, S. B., Carneiro, F. F., Scalabrini, E. B., Shibata, C., & Pessôa, F. S. (2025) · Revista Contemporânea · doi:10.56083/rcv5n7-144 · Cited by 4
Brennan-Davies, A. H., & Lakey, S. (2025) · Cureus · doi:10.7759/cureus.97124
Echocardiographic evaluation and clinical implications of cardiac remodeling in obesity
Okushi, Y., Takahashi, T., & Kusunose, K. (2026) · Journal of Echocardiography · doi:10.1007/s12574-026-00721-6
Neue Medikamente zur Gewichtsreduktion – ethische Herausforderungen
Weidinger, I. S. (2026) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2748-4530
Of Fasts and Feasts: Catholic Ethics and the Right Use of GLP-1 Agonists for Weight Loss
Starr, A. Y. A. (2026) · The Linacre Quarterly · doi:10.1177/00243639261450700
Neue Medikamente zur Gewichtsreduktion – ethische Herausforderungen
Weidinger, I. S. (2026) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2840-0244
Hellgren, J., Herder, T., & Svensson, P. (2026) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2026.2703168
Elkin, J., Schilling, C. G., Thuraisingam, S., Hi, M. W., Sumithran, P., Choong, P., Dowsey, M. M., & Shadbolt, C. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70253
Grenet, G., Eskandari, R., Ko, J., Adams, S. P., Salzwedel, D. M., Heran, B. S., Ambasta, A., Bassett, K., & Thompson, W. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006225
The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review
Lim, Q., Khoo, J. K., Ooi, Y., Ramachandaram, A., & Ratnasingam, J. (2026) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2026.101963
Conaghan, P. G., Rolland, C., Frampton, J., Lavoie, L., Giblin, K., Robinson, R., & Perez‐Nieves, M. (2026) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2026.100875
Huang, Y., Li, P.-Y., Liu, K.-W., Li, P., Chen, S.-C., Chen, J., Meyerowitz‐Katz, G., Huang, J.-Y., & Su, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261490985
Equitable Access to GLP-1 Receptor Agonists—Essential but Not Accessible
Karim, S. A., Faden, R., Searchinger, C., & Bollyky, T. J. (2026) · JAMA · doi:10.1001/jama.2026.15762
Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women
Deanfield, J. E., Wong, J. L. C., Katsoulis, M., Deanfield, E., Thakkar, R., Patel, R. S., Joy, R., Noble, M. J., & Ryan, D. H. (2026) · Nature Medicine · doi:10.1038/s41591-026-04687-x
Jang, R., Jang, M., Ruan, X., Jin, C., & Kim, W. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04199-0
Metadata
- Authors
- Dellgren, J. L., Persad, G., & Emanuel, E. J.
- Affiliations
- University of Bergen (NO)
- University of Denver (US)
- Corresponding author
- Emanuel, Ezekiel J
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 404
- Issue
- 10455
- Pages
- 902-906
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4401630569
- Cited by
- 33
- References
- 19
- Citations by year
- 2026: 18 · 2025: 14 · 2024: 1
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- green
- philpapers.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- PhilPapers (PhilPapers Foundation) (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, obesity treatment, drug coverage policy, health technology assessment, cost-effectiveness analysis, drug pricing, innovation incentives, ethical analysis, high-income countries, drug reimbursement
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
